| |
In the present study,
after D-400 treatment a significant reduction in blood sugar levels
in alloxan induced diabetes was observed, an oral glucose tolerance
test (OGTT) showed a significant lowering of AUC in streptozotocin
induced diabetes in rats. There was a rise in hepatic glycogen level
closer to normal after D-400 treatment. In the pancreas of diabetic
rats, D-400 therapy showed a significant increase in islet number
and beta cell count and appeared to bring about blood glucose homeostasis
by increasing insulin secretion through repair/regeneration of endocrine
pancreas which may be responsible for the prevention of hepatic
glycogenolysis.
Keywords: Alloxan,
streptozotocin; liver glycogen; antihyperglycaemic action; herbal
treatment
In non-insulin dependent
diabetes mellitus (NIDDM), insulin resistance is a major pathophysiologic
factor influencing glucose homeostasis. NIDDM accounts for over
85% of diabetes worldwide and is associated with morbidity and mortality,
resulting from its microvascular, macrovascular and neuropathic
complications (Huse et al., 1988). The treatment of hyperglycaemia
in patients with NIDDM is directed towards achieving euglycaemia
and eliminating or minimizing the chronic complications. Unfortunately,
none of the oral hypoglycaemic agents have been successful in maintaining
euglycaemia, and in addition have a number of side effects (Holman
and Turner, 1991).
In the present study
D-400, a crude drug formulation consisting of herbs and minerals
derived from the traditional system of medicine in India, Ayurveda,
was evaluated for its antihyperglycaemic action.
Animals: Wistar strain albino rats (160-180
g) were used. The rats were housed in colony cages at an ambient
temperature of 25° ± 2° C and 45%-55% relative humidity with 12h
light-dark cycle. The animals had free access to standard pellet
chow (Hindustan Lever Ltd.) and water was given through drinking
bottles. All the experiments were conducted between 0900 and 1400
h.
Test drug: D-400 is a polyherbal formulation
consisting of herbs procured from authentic sources. It consists
of medicinal plants, namely Gymnema sylvestre R. Br. (Asclepiadaceae,
leaves) 30mg, Momordica charantia Linn. (Cucurbitaceae,
fruit) 20mg, Tinospora cordifolia (Wild) (Cucurbitaceae,
fruit) 20mg, Tinospora Cordifolia (Wild) Miers. (Menispermaceae,
stem) 10mg, Perocarpus marsupium Roxb. (Leguminosae, stem)
20mg, Casearia esculenta Roxb. (Samydaceae, stem) 20mg,
Eugenia jambolana Lam. (Myrtaceae, bark) 20mg, Ocimum
sanctum Linn. (Labiatae, whole plant) 10mg, Balsamodendron
mukul Hook. Ex stocks (Burseraceae, resin) 30mg. Shilajit
(purified) 30mg. The drug was suspended in distilled water and
was administered orally through an orogastric tube at a dose of
1 g/kg. The volume of the vehicle being kept constant at 5ml/kg.
Control animals received only the vehicle in the same volume and
through the same route. Alloxan induced diabetes mellitus: Sixteen
female rats were used in this experiment, and fasting blood sugar
was determined after an overnight fast with free access to water.
On the following day, alloxan monohydrate was administered at a
dose of 50mg/kg and stable hyperglycaemia was confirmed on day
8. Twelve rats showing stable hyperglycaemia were divided into two
groups of six rats each. Group 1 received vehicle and group 2 received
D-400. In both the groups after an overnight fast, blood was collected
for blood sugar estimation, on days 20, 30 and 40. On day 42 rats
were killed by decapitation and liver was removed from each rat
for glycogen estimation.
Blood sugar estimation: Blood was collected
by ocular vein puncture under mild ether anesthesia. Blood sugar
estimation was done by using GOD/POD enzymatic method (Teitz, 1976).
Liver glycogen estimation: Liver glycogen estimation was done by
the method as described by Scifter et al., 1949. Immediately after
excision from the animal, approximately 1 g of the liver was dropped
into a previously weighed test tube containing 3ml of 30% potassium
hydroxide solution. The weight of the liver sample was determined.
The tissue was then digested by heating the tube for 20 min in boiling
water bath, and following this the digest was cooled, transferred
quantitatively to a 50ml volumetric flask, and diluted to the mark
with water. The contents of the flask were then thoroughly mixed
and a measured portion was then further diluted with water in a
second volumetric flask so as to yield a solution of glycogen of
3-30 m g/ml. Fiveml aliquots of the final dilution were then pipetted
into Evelyn tubes and the determination with anthrone was carried
out. The amount of glycogen in the aliquot used was then calculated
using the following equation:
m g of glycogen in aliuot = 100 U/1.11S
U is the optical denisty of the unknown solution.
S is the optical density of the 100 m g glucose and 1.11 is the
factor determined by Morris standard (Morris, 1948) for the conversion
of the glucose to the glycogen.
Streptozotocin induced diabetes mellitus:
Diabetes was induced in overnight fasted rats by intravenous (via
tail vein) injection of 50mg/kg streptozotocin (Upjohn) using a
5% solution of freshly prepared streptozotocin in 0.1 M citrate
buffer (pH 4.5). Control rats received citrate buffer only. Fasting
blood glucose was measured and glycosuria was detected in all the
animals. 7 days after streptozotocin administration. Blood glucose
estimation was done on day 7. Eighteen rats showing blood sugar
levels more than 300mg % were selected for the study. They were
divided into two groups of nine rats each. Group I received the
vehicle and Group II received the test drug. After 21 days of treatment,
an oral glucose tolerance test (OGTT) was carried out according
to the method of Cole and Harned (1938) as modified by Wexler and
Fischer (1963). After an overnight fast, blood samples were collected
and then 200mg glucose in 2ml. Solution was administered and blood
samples were collected at 0, 30, 60, 90, 120 and 180 min.
Histologic studies on the pancreas: The
whole pancreas from all 18 animals in the streptozotocin treated
group perfused with formalin was collected and removed immediately
together with the spleen. The three regions of the pancreas, namely
the duodenal (head), gastric (body) and splenic (tail), were dissected
(Jeffe, 1951), cut into smaller fragments and fixed separately in
Bouin’s fluid for 24 h. The segments were dehydrated with ethanol
and embedded in paraffin-wax (56° C). Serial sections (5 m m) were
taken and stained with chrome-haematoxylin and phloxin (Gomori,
1941). Serial sections were studied for the number of islets and
beta cell content in each of the three regions of pancreas from
each rat.
Statistical analysis was done by using unpaired
Student’s t-test. The minimum level of significance was set a p<0.05.
No mortality was observed
in any experimental group throughout the period of investigation
although a steady decline in body weight was observed in the alloxan
treated group. D-400 not only attenuated the decrease in body weight
but induced a steady rise (Table 1). D-400 treatment appeared to
regulate diabetes at the cellular level resulting in declination
of body weight to near normal levels. D-400 treatment resulted in
a significant reduction in blood sugar level in alloxan treated
rats (Table 2). The oral glucose tolerance test following streptozotocin-induced
hyperglycaemia showed a significant reduction of AUC from 71694.80
± 987.57 to 41489.12 ± 584.14 under the influence of D-400. There
was a significant reduction in pancreatic weight, number of islets,
diameter of each islet and beta cell counts/islet in streptozotocin
treated group. Treatment with D-400 resulted in restoration of near
normal architecture of pancreatic islet (Table 3, Figs. 1 and 2).
This suggests a possible regeneration or repair of the cells of
the islets of Langerhans in the streptozotocin treated group, under
the influence of D-400. Unlike sulphonylureas D-400 did not have
any hypoglycaemic effect in normal rats. It is here that D-400 assumes
significance, because of its capacity to partially regenerate the
damaged endocrine tissue so that the islet number increases with
therapy.
| Table
1: Effect of D-400 on body weight profile in alloxan-induced
diabetic rats |
|
Group
|
Body weight (g) mean ± SEM
|
|
Day 0
|
Day 20
|
Day 30
|
Day 40
|
| Vehicle |
157.00 ± 8.75
|
175.00 ± 9.70
|
189.00 ± 9.14
|
198.00 ± 9.30
|
| Alloxan |
163.00 ± 6.00
|
161.00 ± 11.00
|
153.00 ± 9.00
|
158.00 ± 8.00
|
| Alloxan + D-400 |
159.00 ± 5.00
|
158.00 ± 11.00
|
164.00 ± 12.00
|
175.00 ± 10.00
|
| n=6 rats in each experimental
group. |
| Table 2: Effect
of D-400 on fasting blood sugar in alloxan-induced diabetic
rats |
|
Group
|
Blood sugar on days (mg%) mean ± SEM
|
|
Day 0
|
Day 20
|
Day 30
|
Day 40
|
| Vehicle |
79.70 ± 3.37
|
75.90 ± 1.62
|
77.00 ± 4.97
|
77.70 ± 4.29
|
| Alloxan |
343.00 ± 25.00
|
202.00± 26.00
|
228.00 ± 20.00
|
180.00 ± 20.00
|
| Alloxan + D-400 |
341.00 ±23.00
|
137.00 ± 11.00a
|
144.00 ± 19.00a
|
107.00 ± 10.00a
|
| n=6 in each experimental
group; statistical significance ap<0.05
compared with the alloxan-treated group. |
|
Table 3: Effect of D-400
on pancreatic weight, number and size of the islets of
Langerhans and number of beta-cells/islet in streptozotocin
(STZ) induced diabetic rats
|
|
Group
|
Pancreas
weight (g)
|
No. of
islets
|
Diameter
(µm)
|
Beta-cells/islet
|
| Vehicle |
1.120 ± 0.015
|
11.43 ± 0.57
|
296.47 ± 0.381
|
51.00 ± 2.09
|
| STZ |
1.033 ± 0.43a
|
07.34 ± 0.40c
|
68.41 ± 0.071b
|
15.33 ± 0.56d
|
| STZ
+ D-400 |
1.126 ± 0.014a
|
11.09 ± 0.50c
|
163.43 ± 0.320b
|
26.73 ± 1.88d
|
| n=9
rats in each experimental group; statistical significance
(ap<0.05, b,c,dp<0.001
compared with STZ treated group. |
|
|
|
In diabetes, glucose6-phosphatase
increases in the liver, facilitating glucose release into the blood.
The opposing enzyme, which phosphorylates glucose is glucokinase which
decreases in diabetes. As a result, the liver continues to produce
glucose even with severe hyperglycaemia. This results in glycogen
degradation and inhibition of glucose utilization. The elevation of
depressed glycogen stores by D-400 in alloxan treated rats (Fig. 3)
may be attributed to either an inhibition of hepatic glucose output
by improvement in plasma insulin levels or by stimulating the enzyme
glycogen synthetase responsible for the incorporation of glucose moieties
into pre-existing glycogen chains. The findings of the present study
lend credence to the use of D-400 as an anti-hyperglycaemic agent.
-
Cole, V.V., and Harned B.K. (1938). Diatetic
traits in a strain of rats. Endocrinology 23,
318-326.
-
Gomori, G. (1941). Observation with differential
strains on human islets of Langerhans Am. J. Pathol.
17, 395-406.
-
Holman, R.R. and Turner, R.C. (1991). Oral
agents and insulin in the treatment of non-insulin-dependent
diabetes mellitus. In Textbook of Diabetes, 48 ed. By
J.C. Pickup and G. Williams, pp. 463-476. Blackwell Scientific
Publications, Oxford.
-
Huse, D.M., Oster, G., Killen, A.R. Lacey,
M. J. and Golditz, G.A. (1988). The economic costs of non-insulin-dependent
diabetes mellitus. JAMA 262, 2708-2713.
-
Jeffe, F.A. (1951). A quantitative study of
the islets of Langerhans in the rabbit. Anatomci Recurie
111, 109-121.
-
Morris D.L. (1948). Quantitative determination
of carbohydrates with drywood anthrone reagent. Science
107, 254.
-
Scifter, S., Dayton, S., Molic, B., and Mutwzter,
E. (1985). In Archives of Biochemistry p. 191.
-
Tietz, N.W. (1976). In Clinical Guide to
Laboratory Tests, pp. 238-240. W.B. Saunders, Philadelphia.
-
Wexler, B.C, kand Fischer, C.T. (1963). Abnormal
glucose tolerance in repeatedly bred rats and arteriosclerosis.
Nature 200, 122-136
|
 |